The Role of Cardiovascular Imaging and Serum Biomarkers in Identifying Cardiotoxicity Related to Cancer Therapeutics

Ali Agha; Abdulrazzak Zarifa; Peter Kim; Cezar Iliescu; Greg Gladish; Saamir Hassan; Nicolas Palaskas; Jean B. Durand; Yang Lu; Juan Lopez-Mattei

doi:10.14797/mdcj-15-4-258

The Role of Cardiovascular Imaging and Serum Biomarkers in Identifying Cardiotoxicity Related to Cancer Therapeutics

Ali Agha, Abdulrazzak Zarifa, Peter Kim, Cezar Iliescu, Greg Gladish, Saamir Hassan, Nicolas Palaskas, Jean B. Durand, Yang Lu, Juan Lopez-Mattei

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Abstract

Innovations and discoveries in cancer therapeutics have improved survival rates in patients with various types of malignancies. At the same time, physicians are identifying an increased number of patients with treatment-related cardiotoxicity. It is imperative that physicians recognize early treatment-related adverse effects to determine the safest therapeutic options for patients with cancer. This manuscript evaluates the role of cardiovascular imaging and biomarkers in identifying cardiotoxicity trigged by various chemotherapeutic agents and summarizes expert consensus statements regarding cardiotoxicity monitoring.

Original language	English (US)
Pages (from-to)	258-266
Number of pages	9
Journal	Methodist DeBakey cardiovascular journal
Volume	15
Issue number	4
DOIs	https://doi.org/10.14797/mdcj-15-4-258
State	Published - Oct 1 2019

Keywords

CMR
anthracyclines
biomarkers
cardiac magnetic resonance
cardiotoxicity
echocardiogram
immune checkpoint inhibitors

ASJC Scopus subject areas

General Medicine

Access to Document

10.14797/mdcj-15-4-258

Cite this

@article{78d8e80509514505b189661029283983,

title = "The Role of Cardiovascular Imaging and Serum Biomarkers in Identifying Cardiotoxicity Related to Cancer Therapeutics",

abstract = "Innovations and discoveries in cancer therapeutics have improved survival rates in patients with various types of malignancies. At the same time, physicians are identifying an increased number of patients with treatment-related cardiotoxicity. It is imperative that physicians recognize early treatment-related adverse effects to determine the safest therapeutic options for patients with cancer. This manuscript evaluates the role of cardiovascular imaging and biomarkers in identifying cardiotoxicity trigged by various chemotherapeutic agents and summarizes expert consensus statements regarding cardiotoxicity monitoring.",

keywords = "CMR, anthracyclines, biomarkers, cardiac magnetic resonance, cardiotoxicity, echocardiogram, immune checkpoint inhibitors",

author = "Ali Agha and Abdulrazzak Zarifa and Peter Kim and Cezar Iliescu and Greg Gladish and Saamir Hassan and Nicolas Palaskas and Durand, {Jean B.} and Yang Lu and Juan Lopez-Mattei",

year = "2019",

month = oct,

day = "1",

doi = "10.14797/mdcj-15-4-258",

language = "English (US)",

volume = "15",

pages = "258--266",

journal = "Methodist DeBakey cardiovascular journal",

issn = "1947-6094",

publisher = "Methodist DeBakey Heart & Vascular Center",

number = "4",

}

TY - JOUR

T1 - The Role of Cardiovascular Imaging and Serum Biomarkers in Identifying Cardiotoxicity Related to Cancer Therapeutics

AU - Agha, Ali

AU - Zarifa, Abdulrazzak

AU - Kim, Peter

AU - Iliescu, Cezar

AU - Gladish, Greg

AU - Hassan, Saamir

AU - Palaskas, Nicolas

AU - Durand, Jean B.

AU - Lu, Yang

AU - Lopez-Mattei, Juan

PY - 2019/10/1

Y1 - 2019/10/1

N2 - Innovations and discoveries in cancer therapeutics have improved survival rates in patients with various types of malignancies. At the same time, physicians are identifying an increased number of patients with treatment-related cardiotoxicity. It is imperative that physicians recognize early treatment-related adverse effects to determine the safest therapeutic options for patients with cancer. This manuscript evaluates the role of cardiovascular imaging and biomarkers in identifying cardiotoxicity trigged by various chemotherapeutic agents and summarizes expert consensus statements regarding cardiotoxicity monitoring.

AB - Innovations and discoveries in cancer therapeutics have improved survival rates in patients with various types of malignancies. At the same time, physicians are identifying an increased number of patients with treatment-related cardiotoxicity. It is imperative that physicians recognize early treatment-related adverse effects to determine the safest therapeutic options for patients with cancer. This manuscript evaluates the role of cardiovascular imaging and biomarkers in identifying cardiotoxicity trigged by various chemotherapeutic agents and summarizes expert consensus statements regarding cardiotoxicity monitoring.

KW - CMR

KW - anthracyclines

KW - biomarkers

KW - cardiac magnetic resonance

KW - cardiotoxicity

KW - echocardiogram

KW - immune checkpoint inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85078366100&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85078366100&partnerID=8YFLogxK

U2 - 10.14797/mdcj-15-4-258

DO - 10.14797/mdcj-15-4-258

M3 - Review article

C2 - 31988686

SN - 1947-6094

VL - 15

SP - 258

EP - 266

JO - Methodist DeBakey cardiovascular journal

JF - Methodist DeBakey cardiovascular journal

IS - 4

ER -

The Role of Cardiovascular Imaging and Serum Biomarkers in Identifying Cardiotoxicity Related to Cancer Therapeutics

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this